Open AccessDeletion of Rv2571c Confers Resistance to Arylamide Compounds in Mycobacterium tuberculosis
Author(s) -
Catherine Shelton,
Matthew B. McNeil,
Julie V. Early,
Thomas R. Ioerger,
Tanya Parish
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02334-20
Subject(s) - mutant , mycobacterium tuberculosis , complementation , gene , mutation , tuberculosis , medicine , cross resistance , microbiology and biotechnology , genetics , biology , pathology
Tuberculosis, caused by Mycobacterium tuberculosis , is an urgent global health problem requiring new drugs, new drug targets, and an increased understanding of antibiotic resistance. We have determined the mode of resistance to be a series of arylamide compounds in M. tuberculosis .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom